舒利迭治疗对慢性阻塞性肺疾病患者肺功能及血清炎症因子的影响

Effect of seretide treatment on pulmonary function and inflammatory markers in COPD

目的探讨应用沙美特罗/氟替卡松粉吸入剂(舒利迭)在慢性阻塞性肺疾病(COPD)稳定期治疗中对肺功能和全身炎症标记物的影响。方法选取2011年11月至2012年11月在潍坊市人民医院治疗的COPD稳定期患者60例作为研究对象。将所有患者随机分为实验组和对照组,每组各30例。对照组患者给予为期8周的常规止咳、平喘、吸氧等对症支持治疗;实验组在与对照组患者相同治疗的基础上加用沙美特罗/氟替卡松粉吸入剂(舒利迭)治疗,为期8周,单次剂量为50/500μg,每日两次。观察患者治疗前及治疗8周后血清可溶性细胞间黏附分子-1和白细胞介素IL-6、IL-8、IL-17等指标,同时观察两组患者肺功能的变化。结果实验组稳定期COPD患者血清可溶性细胞间黏附分子-1浓度在治疗前后变化差异有统计学意义(P<0.05)。实验组患者治疗后血清IL-6、IL-8、IL-17的水平较治疗前明显降低,差异有统计学意义(P<0.05)。实验组患者肺功能指标FVC、FEV1、FEV1/FVC%在治疗前后有明显统计学差异(P<0.05)。结论通过吸入沙美特罗/氟替卡松粉吸入剂可以明显改善慢性阻塞性肺疾病患者肺功能,降低患者血清中可溶性细胞间黏附分子-1及IL-6、IL-8、IL-17的水平,减轻气道炎性细胞浸润。

Objective To explore the influence of salmeterol/fluticasone（seretide） on systemic inflammatory markers in the treatment of stable chronic obstructive pulmonary disease. Methods All the cases in this study were selected from ward patients in Weifang People＇s Hospital from Nov, 2011 to Nov, 2012. All of the patients with COPD were randomly divided into experimental group and control group, and each group was 30 patients. The patients in control group were giv- en eight-week conventional treatment with relieving cough and oxygen inhalation. The experi mental group received the same treatment. Besides, it received treatment of seretide 50 inhala tion, twice daily, eight weeks, sICAM-I,IL-6, IL-8 and IL-17 before and after treatment in the two groups were all calculated. levels of sICAM-1 in experimental （P〈0.05）. At the same ti lower than before（P〈0. me, 05） Meanwhile, group had sig the levels of IL-6,I pulmonary function was tested. Results The nificant L-8 and differences before and after treatment（P IL-17 after treatment were significantly The markers of pulmonary function in experimental group had sig nificant differences before and after treatment（P〈0.05）. Conclusion Seretide in stable COPD can significantly 1, IL-6, IL-8, I improve pulmonary function of patients. It also can reduce the levels of sICAM L-17 and control airway inflammation.